Regeneron’s monoclonal antibody trevogrumab, with or without the anti-activin A antibody garetosmab, appears to preserve lean ...

In patients with T2D, the risks for gastroesophageal reflux disease and related complications are greater with GLP-1 RA ...

Patients with systemic lupus erythematosus (SLE) and type 2 diabetes, with and without lupus nephritis (LN), had a lower risk ...

USA: A new study published in Arthritis & Rheumatology found that patients with lupus and type 2 diabetes, including those ...

Taiwan: A recent study has found that the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type ...

Hanmi Pharmaceutical's "Efeglenatide," the first domestically developed GLP-1 (glucagon-like peptide-1) obesity drug in Korea, is set to expand its ...

Two main types of autoimmune pancreatitis (AIP) have been described: type 1, linked to IgG4-related disease, and type 2, associated with inflammatory bowel diseases. Recently, a third type has been ...

Patients prescribed glucagon-like peptide-1 receptor agonists have roughly half the risk of developing noninfectious uveitis.

Protheragen announced an expanded global supply of GLP-1 agonist APIs to meet rising demand for diabetes and obesity treatments.

Addressing obesity and fibromyalgia are essential components to managing the most complex patients with psoriatic arthritis, ...

This 3-part series looks at the current evidence for the treatment of SUDs. Part 2 reviews the use of GLP-1 receptor agonists and alcohol use disorder.

PATIENTS with systemic lupus erythematosus (SLE) and Type 2 diabetes (T2D) had significantly lower cardiovascular, kidney, ...